COGNITION THERAPEUTICS INC (CGTX)
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Cognition Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 95.09M shares outstanding
USCognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments.
The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders.
Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB).
Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD).
The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
Leadership
Aaron Fletcher, Ph.D.
Director
Brett P. Monia, Ph.D.
Director
Ellen B. Richstone
Director
Jack A. Khattar
Chair
Employees
14
Country
US
Sector
Healthcare
Website
cogrx.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Fletcher Aaron G.L. | Director | Grant/Award | 25.0K | -- | Jun 17, 2026 |
 Khattar Jack A. | Director | Grant/Award | 25.0K | -- | Jun 17, 2026 |
 Monia Brett P | Director | Grant/Award | 25.0K | -- | Jun 17, 2026 |
 Wallace Peggy | Director | Grant/Award | 25.0K | -- | Jun 17, 2026 |
 RICHSTONE ELLEN B | Director | Grant/Award | 25.0K | -- | Jun 17, 2026 |
 Doyle John Brendan | Chief Financial Officer | Automatic Sell | 8.6K | $11.0K | May 1, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
BIOS Capital Management, LP | 6.0M | 6.3% | 13F |
DAVENPORT & Co LLC | 4.2M | 4.5% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 3.4M | 3.6% | 13F |
 Ricciardi Lisa CEO & President, Director | 1.7M | 1.8% | FORM 4 |
27-4413262 · may incl. warrants· stale · filed Feb 2024 | 1.4M | 1.5% | 13G |
BIOS MEMORY SPV I, LP · may incl. warrants· reaffirmed 13F Aug 2026 | 1.4M | 1.5% | 13D |
BlackRock, Inc. | 1.3M | 1.3% | 13F |
Chescapmanager LLC | 997.0K | 1.0% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 910.0K | 1.0% | 13F |
 Caggiano Anthony Chief Medical Officer | 874.9K | 0.9% | FORM 4 |
Insiders
- Fletcher Aaron G.L.Director
- Khattar Jack A.Director
- Monia Brett PDirector
- Wallace PeggyDirector
- RICHSTONE ELLEN BDirector
- Doyle John BrendanChief Financial Officer
- Caggiano AnthonyChief Medical Officer
- Ricciardi LisaCEO & President
- Kreis Leslie W.Director
based on 95.09M shares outstanding
US30d Avg
613.60K
60d Avg
515.10K
90d Avg
522.73K